Philips' direct-to-angio stroke pathway: new analysis demonstrates substantial cost savings in addition to improved patient outcomes
14 Juin 2023 - 10:00AM
Philips' direct-to-angio stroke pathway: new analysis demonstrates
substantial cost savings in addition to improved patient outcomes
June 14, 2023
Economic analysis of cost of Vall d’Hebron University Hospital
Stroke Unit shows direct-to-angio stroke pathway can save more than
USD 3,000 per patient
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced the results of a health economic analysis published in
the Journal of NeuroInterventional Surgery (JNIS) that show an
innovative approach to the stroke care pathway reduced costs by an
average of EUR 2,848 (~USD 3,120) per patient. The retrospective
analysis looked at data from the controlled single-center ANGIOCAT
clinical trial conducted at the Vall d’Hebron University Hospital
Stroke Unit (Barcelona, Spain) [1]. Earlier results from this study
demonstrated that a ‘Direct-to-Angio Suite’ (DTAS) pathway improves
clinical outcomes for patients who have suffered a stroke.
“The ANGIOCAT clinical study has already shown that bringing
stroke patients directly to the angio suite improves patient
outcomes. The economic analysis of the data now tells us we can
also significantly reduce costs,” said Dr. Manuel Requena, Stroke
and Interventional Neurologist, University Hospital Vall d’Hebron.
“This indicates that the initial up-front investment of a
direct-to-angio suite workflow will result in a fast return on
investment for healthcare providers.”
Innovating the stroke pathwayAfter initial
triage in the emergency department, the typical treatment pathway
for stroke involves sending the patient to the radiology department
for a diagnostic CT or MRI brain scan. This adds time, often
worsened by gaps in communication, information, and access to
stroke expertise. For stroke centers, a time-saving alternative is
to have a dedicated angio-suite permanently on standby, to which
stroke patients can be transferred immediately after admission.
Using cone-beam CT imaging, such as that built into Philips Image
Guided Therapy System – Azurion, clinicians can make a diagnosis
and intervene on-the-spot, saving precious time. The health
economics analysis indicates that a positive return on investing in
a dedicated angio suite can be achieved in only a few years.
Philips cone-beam CTPhilips’ DTAS workflow is
enabled by an advanced cone-beam computed tomography (CBCT) brain
scan performed directly in the angio suite to diagnose patients.
CBCT utilizes a cone-shaped beam of X-rays and a flat-panel
detector mounted on a C-arm gantry similar to that routinely used
in an angio suite, capturing multiple images from different angles
to reconstruct 3D images of the brain. Thanks to technology
breakthroughs, Philips has increased the diagnostic confidence of
CBCT from 32% to 93% in the space of a few years [3][4][5]. This
technology can rule out intracranial hemorrhages and identify large
vessel occlusions (LVOs), which account for roughly a quarter to a
half of acute ischemic strokes [2]. Patients diagnosed with an LVO
can then be immediately operated on using a minimally invasive
image-guided procedure known as a mechanical thrombectomy to open
up the blocked artery causing their stroke.
Lower cost, better patient outcomesMultiple
single-center studies have shown the positive impact of DTAS on
clinical outcomes with the result that many dedicated stroke
centers have already adopted it. A large multi-center randomized
clinical trial called WE-TRUST (Workflow Optimization to Reduce
Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
[8] is currently running to confirm the patient benefit of
DTAS.
Philips’ stroke portfolio includes solutions for stroke
monitoring and communication in ambulances, tele-stroke patient
assessment, diagnostic imaging and analysis, image-guided therapy,
neurological monitoring and assessment, and more. Its image-guided
stroke therapy solutions are based on the Philips Image Guided
Therapy System – Azurion.
[1] Requena M, Vanden Bavière H, Verma S, et al. Cost-utility of
direct transfer to angiography suite (DTAS) bypassing conventional
imaging for patients with acute ischemic stroke in Spain: results
from the ANGIOCAT trial.Journal of NeuroInterventional Surgery
Published Online First: 27 April 2023. doi:
10.1136/jnis-2023-020275[2] World Stroke Organization (WSO): Global
Stroke Fact Sheet 2022
(https://www.world-stroke.org/assets/downloads/WSO_Global_Stroke_Fact_Sheet.pdf)[3]
Nicholson P, Cancelliere NM, Bracken J, et al. Novel flat-panel
cone-beam CT compared to multi-detector CT for assessment of acute
ischemic stroke: A prospective study. Eur J Radiol. 2021
May;138:109645. doi: 10.1016/j.ejrad.2021.109645. Epub 2021 Mar 10.
PMID: 33725654.[4] Cancelliere NM, Hummel E, van Nijnatten F, et
al. The butterfly effect: improving brain cone-beam CT image
artifacts for stroke assessment using a novel dual-axis trajectory.
J Neurointerv Surg. 2023 Mar;15(3):283-287. doi:
10.1136/neurintsurg-2021-018553. Epub 2022 Apr 27. PMID: 35478176;
PMCID: PMC9985729.[5] Cancelliere NM, van Nijnatten F, Hummel E, et
al. Motion artifact correction for cone beam CT stroke imaging: a
prospective series. J Neurointerv Surg. 2022 Dec
23:neurintsurg-2021-018201. doi: 10.1136/jnis-2021-018201. Epub
ahead of print. PMID: 36564201.[6] WE-TRUST. Workflow optimization
to reduce time to endovascular reperfusion for ultra-fast stroke
treatment, ClinicalTrials. gov, U.S. National Library of Medicine,
identifier: NCT04701684. n.d. Available:
https://clinicaltrials.gov/ct2/show/ NCT04701684. The WE-TRUST
study is sponsored by Philips.
For further information, please contact:
Joost Maltha Philips Global Press Office Tel:
+31 6 10 55
8116 Email: joost.maltha@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being through meaningful innovation. Philips’ patient- and
people-centric innovation leverages advanced technology and deep
clinical and consumer insights to deliver personal health solutions
for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring
and enterprise informatics, as well as in personal health. Philips
generated 2022 sales of EUR 17.8 billion and employs approximately
74,000 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
Koninklijke Philips NV (TG:PHI1)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Koninklijke Philips NV (TG:PHI1)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024